In two randomized, crossover studies, the addition of 45 mg/day pioglitazone to rheumatoid arthritis patients’ baseline disease-modifying antirheumatic drug (DMARD) therapy yielded a significant improvement in patient-reported global health and pain score, along with a significant reduction in the DAS28-CRP level [260,261]. The gene discussed is CRP; the disease is rheumatoid arthritis.